ClinicalTrials.gg
CompletedNCT04647487EMBER-2Updated Nov 12, 2025Results posted

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

A Phase 1 interventional study of LY3484356 in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 19 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
52nd of 80
87 · median 138
Started
2021
with 3 others
Phase 1
17 of 88
3 open now
Registered
74th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 52nd largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 in phase 1, and was the 74th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • SERD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed invasive ER+, - breast carcinoma
  • Be willing and able to provide pre- and on-treatment tumor samples
  • Have a performance status of 0 or 1 on the scale
  • Have adequate organ function
  • Be able to swallow capsules
  • Be a woman

Exclusion criteria

Exclusion Criteria:

  • Have bilateral invasive breast cancer
  • Have breast cancer
  • Plan to receive concurrent therapy with any other non-protocol anti-cancer therapy
  • Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer
  • Have had prior radiotherapy to the ipsilateral chest wall for any
  • Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer
  • Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment
  • Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)
  • Have certain infections such as hepatitis or tuberculosis or that are not well controlled
  • Have another serious medical condition
  • Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    200 milligrams (mg) LY3484356

    Participants received 200 mg LY3484356 administered orally once daily for 15 days

    Drug: LY3484356

  • Experimental
    400 mg LY3484356

    Participants received 400 mg LY3484356 administered orally once daily for 15 days

    Drug: LY3484356

  • Experimental
    800 mg LY3484356

    Participants received 800 mg LY3484356 administered orally once daily for 15 days

    Drug: LY3484356

Interventions

  • Administered orally.

    Also known as: Imlunestrant

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Estrogen Receptor (ER) Expression

    Tumor tissue collected by biopsy is used to determine ER expression. ER expression is measured by immunohistochemistry (IHC) and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total ER H-score ranged from 0 to 300, where a higher score indicated stronger ER expression. Percent change in ER expression was defined as 100\*(ER expression on-treatment - ER expression pre-treatment)/(ER expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(ER expression on-treatment/ER expression pre-treatment).

    Time frame: Baseline, Day 15

Secondary outcomes

  1. Percent Change From Baseline in Ki-67

    Tumor tissue collected by biopsy is used to determine Ki-67 expression. It is measured by IHC and the Ki-67 index is defined as the percent of cells staining positive by validated central assay. Percent change in Ki-67 index was defined as 100\*(Ki-67 index on-treatment - Ki-67 index pre-treatment)/(Ki-67 index pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(Ki-67 index on-treatment/Ki-67 index pre-treatment).

    Time frame: Baseline, Day 15

  2. Percent Change From Baseline in Progesterone Receptor (PR) Expression

    Tumor tissue collected by biopsy is used to determine PR expression. PR expression is measured by IHC and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total PR H-score ranged from 0 to 300, where a higher score indicated stronger PR expression. Percent change in PR expression was defined as 100\*(PR expression on-treatment - PR expression pre-treatment)/(PR expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(PR expression on-treatment/PR expression pre-treatment).

    Time frame: Baseline, Day 15

  3. Pharmacokinetics (PK): Plasma Concentration of LY3484356

    Plasma Concentration of LY3484356 evaluated using sparse sampling methodology

    Time frame: Day 1: 3.5 hours (h) postdose; Day 8: Predose; Day 8: 3.5 h postdose

07

Results

Posted Nov 12, 2025

Participant flow

Participant flow — Overall Study
Milestone200 mg LY3484356400 mg LY3484356800 mg LY3484356
Started283029
Received at least one dose of study drug283028
Completed273026
Not completed103
Withdrew: Protocol deviation001
Withdrew: Withdrawal by subject102

Outcome measures

PrimaryPercent Change From Baseline in Estrogen Receptor (ER) Expression

Tumor tissue collected by biopsy is used to determine ER expression. ER expression is measured by immunohistochemistry (IHC) and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total ER H-score ranged from 0 to 300, where a higher score indicated stronger ER expression. Percent change in ER expression was defined as 100\*(ER expression on-treatment - ER expression pre-treatment)/(ER expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(ER expression on-treatment/ER expression pre-treatment).

Time frame:
Baseline, Day 15
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Estrogen Receptor (ER) Expression
percent change200 mg LY3484356400 mg LY3484356800 mg LY3484356
Percent Change From Baseline in Estrogen Receptor (ER) Expression-88.89 (-95.62 to -71.85)-81.50 (-91.34 to -60.47)-70.13 (-78.38 to -58.75)
SecondaryPercent Change From Baseline in Ki-67

Tumor tissue collected by biopsy is used to determine Ki-67 expression. It is measured by IHC and the Ki-67 index is defined as the percent of cells staining positive by validated central assay. Percent change in Ki-67 index was defined as 100\*(Ki-67 index on-treatment - Ki-67 index pre-treatment)/(Ki-67 index pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(Ki-67 index on-treatment/Ki-67 index pre-treatment).

Time frame:
Baseline, Day 15
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Ki-67
percent change200 mg LY3484356400 mg LY3484356800 mg LY3484356
Percent Change From Baseline in Ki-67-68.56 (-78.71 to -53.59)-70.61 (-80.04 to -56.73)-72.28 (-81.22 to -59.09)
SecondaryPercent Change From Baseline in Progesterone Receptor (PR) Expression

Tumor tissue collected by biopsy is used to determine PR expression. PR expression is measured by IHC and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total PR H-score ranged from 0 to 300, where a higher score indicated stronger PR expression. Percent change in PR expression was defined as 100\*(PR expression on-treatment - PR expression pre-treatment)/(PR expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(PR expression on-treatment/PR expression pre-treatment).

Time frame:
Baseline, Day 15
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Progesterone Receptor (PR) Expression
percent change200 mg LY3484356400 mg LY3484356800 mg LY3484356
Percent Change From Baseline in Progesterone Receptor (PR) Expression-85.44 (-96.61 to -37.36)-75.56 (-90.33 to -38.20)-82.01 (-91.98 to -59.66)
SecondaryPharmacokinetics (PK): Plasma Concentration of LY3484356

Plasma Concentration of LY3484356 evaluated using sparse sampling methodology

Time frame:
Day 1: 3.5 hours (h) postdose; Day 8: Predose; Day 8: 3.5 h postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics (PK): Plasma Concentration of LY3484356
nanograms/milliliter (ng/mL)200 mg LY3484356400 mg LY3484356800 mg LY3484356
Day 1 (3.5 h Postdose)25.3 ± 7486.9 ± 82106 ± 107
Day 8 (Predose)33.0 ± 7074.3 ± 7799.6 ± 87
Day 8 (3.5 h Postdose)55.2 ± 58120 ± 63225 ± 77

Adverse events

Collected over Baseline until end of follow-up (up to 63 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg LY34843560/28 (0%)1/28 (3.6%)15/28 (53.6%)
400 mg LY34843560/30 (0%)2/30 (6.7%)12/30 (40%)
800 mg LY34843560/28 (0%)1/28 (3.6%)15/28 (53.6%)
Most frequent serious events
Most frequent serious events
Event200 mg LY3484356400 mg LY3484356800 mg LY3484356
Post procedural haematomaInjury, poisoning and procedural complications0/282/300/28
DiverticulitisInfections and infestations0/280/301/28
MastitisInfections and infestations1/280/300/28
Wound dehiscenceInjury, poisoning and procedural complications1/280/300/28
Most frequent other events
Showing 10 of 12
Most frequent other events
Event200 mg LY3484356400 mg LY3484356800 mg LY3484356
DiarrhoeaGastrointestinal disorders3/283/309/28
NauseaGastrointestinal disorders3/281/304/28
Hot flushVascular disorders4/282/302/28
AstheniaGeneral disorders0/284/301/28
LeukopeniaBlood and lymphatic system disorders3/280/300/28
FatigueGeneral disorders2/282/303/28
ArthralgiaMusculoskeletal and connective tissue disorders1/281/302/28
DizzinessNervous system disorders2/280/300/28
HeadacheNervous system disorders2/282/302/28
Breast painReproductive system and breast disorders2/282/302/28

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)200 mg LY3484356400 mg LY3484356800 mg LY3484356Total
Median63.0 (50 to 74)63.5 (50 to 83)64.0 (50 to 83)63.5 (50 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)200 mg LY3484356400 mg LY3484356800 mg LY3484356Total
Female28302886
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg LY3484356400 mg LY3484356800 mg LY3484356Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White27272377
More than one race0000
Unknown or Not Reported0358
Region of Enrollment
Region of Enrollment(Participants)200 mg LY3484356400 mg LY3484356800 mg LY3484356Total
Spain613928
Belgium66719
Germany57618
United States103518
France0112
United Kingdom1001
Estrogen Receptor (ER) Expression
Estrogen Receptor (ER) Expression(H-score)200 mg LY3484356400 mg LY3484356800 mg LY3484356Total
Mean256.82 ± 42.33289.81 ± 17.18292.5 ± 13.36281.07 ± 30.35
08

Study locations

19 sites
  • Winship Cancer Center Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern Memorial Hosptial
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Institut Jules Bordet
    Brussel - Capital, 1070, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hôpital René Huguenin
    Saint-Cloud, Hauts-de-Seine 92210, France
  • Universitätsklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
  • Helios Kliniken Schwerin
    Schwerin, Mecklenburg-Vorpommern 19049, Germany
  • Klinikum der Universitaet Muenchen
    München, 80336, Germany
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Madrid Norte Sanchinarro
    Madrid, 28050, Spain
  • The Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Barts Cancer Institute
    London, London City EC1A 7BE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2022, 18 months.

Results were first posted in Nov 2025, 3 years after primary completion.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 18 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 1, 2020
StartActual
Apr 21, 2021
Primary completionActual
Nov 11, 2022
CompletionActual
Nov 11, 2022
Results first posted
Nov 12, 2025
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04647487
Responsible party
Sponsor
First posted
Dec 1, 2020
Start date
Apr 21, 2021
Primary completion
Nov 11, 2022
Completion
Nov 11, 2022
Results posted
Nov 12, 2025
Last update
Nov 12, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion